Metastatic DTC: FDG uptake on PET/CT predicts poor response to radioiodine

  • Kang SY & al.
  • PLoS One
  • 1 Jan 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Fluorodeoxyglucose (FDG) uptake on positron emission tomography/CT (PET/CT) is negatively associated with response rate and disease control rate in patients with metastatic differentiated thyroid cancer (DTC) treated with radioactive iodine (RAI).

Why this matters

  • Predicting response to RAI can help plan long-term treatment strategies.

Key results

  • FDG uptake was negatively correlated with response rate (OR, 0.233; P=.016).
  • In analysis according to the concordance rate of both tracers, RAI uptake was correlated with response rate (OR, 5.833; P=.01), while FDG uptake was inversely associated with disease control rate (OR, 0.241; P=.034).
  • In lesion-based subgroup analysis, RAI uptake was correlated with disease control rate (OR, 5.2; P=.001), while FDG uptake was inversely correlated with disease control rate (OR, 0.095; P=.002).

Study design

  • 54 patients with metastatic DTC treated with RAI therapy received FDG PET/CT and were analyzed for response and disease control rates.
  • Funding: Drug Development Research, funded by the Ministry of Health & Welfare, Republic of Korea.

Limitations

  • Retrospective study.
  • Small patient sample size.